United States: Case Study: Jazz Pharmaceuticals v. Amneal Pharmaceuticals

On July 13, 2018, the Federal Circuit decided Jazz Pharmaceuticals, Inc. v. Amneal Pharmaceuticals, LLC (Fed. Cir. Jul. 13, 2018), an appeal of six inter partes review decisions by the Patent Trial and Appeal Board's (PTAB) finding that certain claims of seven patents (U.S. Patent Nos. 7,668,730; 7,765,106; 7,765,107; 7,895,059; 8,589,182; 8,457,988; and 8,731,963) covering a computerized risk-management system for the narcolepsy drug Xyrem were invalid as obvious in light of prior art.

Xyrem, marketed by Jazz Pharmaceuticals, Inc. (Jazz), treats daytime sleepiness and muscle weakness in narcolepsy patients. Xyrem's active ingredient has the potential for abuse as a date rape drug; therefore, the Food and Drug Administration (FDA) only allows restricted distribution of the drug. Because of this abuse potential, during the review process for Xyrem, FDA scheduled an advisory committee meeting to discuss risk management-related issues. A Federal Register Notice, dated May 14, 2001, included an announcement of the committee meeting and added a publicly available hyperlink to an FDA webpage where a user could access background materials, meeting minutes, transcripts, and slides from the FDA meeting (referred to as Advisory Committee Art by the PTAB; hereinafter ACA materials).

Amneal Pharmaceuticals, LLC requested inter partes review of the seven patents owned by Jazz and argued that the ACA materials constituted prior art to the patents. Jazz argued that the ACA materials could not be prior art as they were not sufficiently accessible to the public. The PTAB disagreed with Jazz and found that the materials were publicly accessible, because a person of ordinary skill in the art (POSA) would have been motivated to look for notices related to drug distribution or abuse prevention and would have been capable of locating the ACA materials. On the basis of this prior art disclosure, the PTAB found that certain claims of each of the patents would have been obvious. 

Jazz appealed the PTAB's decision to the U.S. Court of Appeals for the Federal Circuit. On July 13, 2018, the Federal Circuit affirmed the PTAB's decision. The primary issue on appeal with respect to the ACA materials was whether they were publicly available before the critical date of the patents. Jazz's principal argument was that the PTAB failed to "make the requisite finding that a [POSA] exercising reasonable diligence could have located the ACA materials." Jazz also argued that Amneal failed to submit any evidence of searchability or indexing of the ACA materials and, to appear in a public search, the ACA materials must be indexed and made searchable.

The Federal Circuit rejected both of Jazz's arguments and concluded that the ACA materials were publicly available and no searchability or indexing of the ACA materials was required to make them publicly available. According to the Federal Circuit, the ACA materials were publicly available and, therefore, printed publications and prior art to the Xyrem patents because: (1) the ACA materials were disseminated widely through the Federal Register; (2) the ACA materials were accessible to the public for a substantial time (i.e. at least two months) prior to the critical date of the Xyrem patents; (3) the ACA materials were disclosed through public domain sources (i.e., FDA publicly announced the committee meeting in the Federal Register and the notice included a hyperlink to the ACA materials on a public federal agency website) thereby "plainly indicat[ing] that there was no reasonable expectation that the ACA materials would remain confidential"; and (4) a POSA "would have been familiar with the Federal Register and motivated to look for notices related to drug distribution, safety, or abuse prevention." Further, the Federal Circuit held that indexing or searchability is not always necessary in case of a printed publication for it to be prior art and, in any event, the Federal Register was sufficiently indexed.

Despite the Federal Circuit's reliance on the Federal Register in this case, it was not willing to establish as a per se rule that every Federal Register notice is prior art. The Federal Circuit will not endorse a rule that would do away with the need for a case-by-case analysis on these issues.

This decision not only impacts Federal Register notices or advisory committee meetings; it also could affect all meetings with FDA where material presented might be publicly available in unredacted, redacted, or summary form, such as presubmission meeting minutes and summary basis of approval publications. For example, in June 2018, FDA issued a Draft Guidance for Industry, entitled "Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program." In this Draft Guidance, FDA discusses Q-submissions (or Q-Subs), which include presubmissions for feedback from FDA prior to submitting premarket submissions (such as IDE, PMA, HDE, De Novo requests, 510(k), INDs, and the like), submission issue requests (SIRs), study risk determinations, and informational meetings. FDA states that Q-Subs are tracked and used at different points throughout the total product life cycle. While the Q-submissions are voluntary, they cannot be withdrawn after feedback is provided and the file closed. FDA assures that it "will keep the existence of Q-submissions confidential, subject to the confidentiality provisions of the [Food, Drug, and Cosmetic Act], FDA's Part 20 regulations covering information disclosure, and the Freedom of Information Act." Nevertheless, under the Freedom of Information Act, all meetings are subject to disclosure review and those records will be provided upon request unless they have been classified as a trade secret or commercially confidential. This includes meeting minutes, transcripts, videos, and materials. Although FDA has a policy of providing predisclosure notification to the submitter as outlined in 21 C.F.R. § 20.61, the Federal Circuit's decision in Jazz makes it clear that companies need to be careful about the way in which information is provided to FDA prior to the priority date for their patents.

Originally published in the October/November 2018 edition of FDLI Update.

Disclaimer: This Alert has been prepared and published for informational purposes only and is not offered, nor should be construed, as legal advice. For more information, please see the firm's full disclaimer.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
Marshall, Gerstein & Borun LLP
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Marshall, Gerstein & Borun LLP
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions